Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=10 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
Ovulation Disorder · Ovarian Cysts
Primary: Number of Participants With Progesterone Level Greater Than 1.5 ng/mL — 9; 10 Participants
Phase 3 N=39 LutrePulse Hypogonadotropic Hypogonadism
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
N/A N=64 Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
Phase 4 N=226 Obesity, Oral Contraception, and Ovarian Suppression
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
Phase 2 N=271 Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction
Anovulation
Primary: Ovulation Rate in Cycle 1 — 64.9; 30.4; 36.8; 35.9 percentage of subjects
Phase 3 N=24 Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
N/A N=20 The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation
Ovulation · Luteal Development
Primary: Number of Cycles With Ovulation Dysfunction When Taken After Ovulation: Extended Luteal Phase — 1; 6; 5 Participants
N/A N=11 The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle
Ovulation (Follicular Rupture Yes/no) · Menstrual Cycles (Total Length, Bleeding Days) · Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Primary: Menstrual Cycle Length — 28.5; 27.2 Days
N/A N=49 Feasibility Study for Development of an Early Test for Ovarian Failure
Healthy · Premature Ovarian Failure
Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants
N/A N=62 Reproductive Hormonal Alterations in Obesity
Obesity
Primary: Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1) — 4.1; 3.6 IU/L
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
N/A N=39 Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Percent Change of 17-OHP Levels From Baseline — 67; 140 percent change
Phase 3 N=25 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Serum 17OHP Responses to hCG — 2.0; 1.2; 1.1; 1.0 ng/ml — p=<0.05
Early Phase 1 N=100 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Polycystic Ovary Syndrome · Infertility
Primary: Ovulation Rate — 93; 108 percentage of all cycles
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
N/A N=79 Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss
Weight Loss · Anovulation · Amenorrhea
Primary: Change From Baseline Ovulatory/Menstrual Function — 12; 18 Participants
Early Phase 1 N=40 Ovarian Function With ENG Implant and UPA Use
Contraception
Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants
Phase 2 N=666 A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
Contraception
Primary: Percentage of Participants With Ovulation Incidence, by Cycle — 0; 0; 0; 0 Percentage of Participants
Phase 1 N=12 Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Pregnancy · Contraception
Primary: Part 1: Serum Medroxyprogesterone Acetate (MPA) Concentration at Day 1 — 0.36; 0.67 nanograms (ng)/milliliter (mL)
Phase 3 N=82 Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Polycystic Ovary Syndrome
Primary: Percentage of Participants With Ovulation Detected by Ultrasound — 52.5; 40.4 percentage of participants — p=0.3
Phase 4 N=3 Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures
Infertility
Primary: Fetal Heart Activity 1 Month After Oocyte Retrieval — 0; 0 participants with fetal heart activity
Phase 3 N=81 Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
Anovulation · Oligo-ovulation · Hypothalamic-pituitary Dysfunction
Primary: Percentage of Subjects With Ovulation Mid-luteal Serum Progesterone (P4) Level of Greater Than or Equal (>=) 5 Nanogram Per Milliliter (ng/mL) or Clinical Pregnancy…
N/A N=20 Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation
Mood
Primary: Follicular Cycle Total Behavioral Score for Calendar of Premenstrual Experiences (COPE) Self Assessment — 3; 5 units on a scale
N/A N=700 Ulipristal Emergency Contraception Used Before or After Ovulation
Contraception
Primary: Percentage of Pregnancies Prevented (PPP) — 77.5; 36.9 percentage of pregnancies prevented — p=<0.0001
Phase 2 N=123 Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control
Ovulation Suppression
Primary: Ovulation Suppression in Three Treatment Groups Over 3 Cycles — 36.5; 20.7; 11.5; 36.9 %of cycles with possible ovulation
Phase 2 N=59 GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Amenorrhea · Premature Ovarian Failure · Ovarian Function Insufficiency
Primary: Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide — 37 participants
Phase 3 N=61 A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021
Healthy
Primary: Serum Estradiol Levels by Cycle Day — 47.00; 51.50; 62.50; 34.50 pg/mL — p=0.6346
N/A N=90 Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women
Polycystic Ovary Syndrome · c Type Natriuretic Peptide · Menstrual Irregularity
Primary: Serum CNP Levels of PCOS and Healthy Participants — 110; 57 pg/ml — p=0.004
Phase 1 N=34 Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…